Who is sponsoring NCT00938184?

NCT00938184 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00938184?

Interventions in NCT00938184: Paroxetine 12.5 milligrams tablet, Paroxetine 25 milligrams tablet, Paroxetine 50 milligrams tablet.

What condition does NCT00938184 study?

NCT00938184 studies Depressive Disorder.

Is NCT00938184 still recruiting?

NCT00938184 is currently completed. Last updated 19 June 2018.

Last reviewed 2018-06-19 · How we verify

NCT00938184

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects

Completed Phase 1 Last updated 19 June 2018

What this trial tests

Phase 1 trial testing Paroxetine 12.5 milligrams tablet in Depressive Disorder in 18 participants. Completed in 2 September 2009.

Timeline

14 July 2009

Primary endpoint
2 September 2009

2 September 2009

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	18
Start date	14 July 2009
Primary completion	2 September 2009
Estimated completion	2 September 2009
Sites	1 location across Japan

Drugs / interventions tested

Paroxetine 12.5 milligrams tablet — full drug profile →
Paroxetine 25 milligrams tablet — full drug profile →
Paroxetine 50 milligrams tablet — full drug profile →

Conditions studied

Depressive Disorder — all drugs for Depressive Disorder →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 20 to 64, male only, with Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to to assess the pharmacokinetics of paroxetine after single doses of paroxetine CR at the dose levels of 12.5, 25 and 50mg in healthy Japanese male volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Depressive Disorder

Currently open trials in the same condition.

NCT07290153 — Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC · recruiting
NCT07100951 — Comparing Brief Psychoanalytic Couple Therapy and Emotionally Focused Therapy in Reducing Relationship Distress · NA · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT06901739 — Therapeutic Potential of a Synbiotic to Improve Mental Health in Subjects With Obesity. · NA · recruiting
NCT06724666 — Transdiagnostic Internet-delivered Intervention for Adolescents With Anxiety and Depression · NA · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00938184 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 19 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00938184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing